Skip to main content

Advertisement

SpringerLink
Log in

A complex substitute: antibody therapy for hemophilia

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Deficiency of the procoagulant cofactor factor VIII (FVIII) in hemophilia A is routinely treated by protein replacement therapy with plasma-derived or recombinant FVIII. Now, a humanized bispecific antibody has been demonstrated to perform the 'scaffold' function of FVIII and could potentially function as a FVIII substitute as a treatment for this inherited bleeding condition (pages 1570–1574).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: A bispecific antibody therapy to restore cofactor activity in the intrinsic tenase complex in hemophilia A.

References

  1. World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2010. <http://www.wfh.org/en/page.aspx?pid=878> (2010).

  2. Bolton-Maggs, P.H. & Pasi, K.J. Lancet 361, 1801–1809 (2003).

    Article  CAS  Google Scholar 

  3. Key, N.S. & Negrier, C. Lancet 370, 439–448 (2007).

    Article  CAS  Google Scholar 

  4. Mei, B. et al. Blood 116, 270–279 (2010).

    Article  CAS  Google Scholar 

  5. Powell, J.S. et al. Blood 119, 3031–3037 (2012).

    Article  CAS  Google Scholar 

  6. Kitazawa, T. et al. Nat. Med. 18, 1570–1574 (2012).

    Article  CAS  Google Scholar 

  7. Nilsson, I.M., Berntorp, E., Lofqvist, T. & Pettersson, H. J. Intern. Med. 232, 25–32 (1992).

    Article  CAS  Google Scholar 

  8. Manco-Johnson, M.J. et al. N. Engl. J. Med. 357, 535–544 (2007).

    Article  CAS  Google Scholar 

  9. Hay, C.R.M. et al. Blood 117, 6367–6370 (2011).

    Article  CAS  Google Scholar 

  10. Astermark, J. et al. Blood 109, 546–551 (2007).

    Article  CAS  Google Scholar 

  11. Fay, P.J. Blood Rev. 18, 1–15 (2004).

    Article  Google Scholar 

  12. De Groot, A.S. & Moise, L. Curr. Opin. Drug Discov. Devel. 10, 332–340 (2007).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. David Lillicrap is in the Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, Ontario, Canada.,

    David Lillicrap

Authors
  1. David Lillicrap
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Lillicrap.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lillicrap, D. A complex substitute: antibody therapy for hemophilia. Nat Med 18, 1460–1461 (2012). https://doi.org/10.1038/nm.2959

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2959

  • Springer Nature America, Inc.

Search

Navigation